Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Jan 20, 2023 3:18pm
289 Views
Post# 35236300

Here's my best i-Dialco guess

Here's my best i-Dialco guess(and it shouldn't have to be a guess)
  • Infomed to take the lead on US Distribution efforts (and fund the costs of same)
  • hire the right team, including a new President, based in the US (big $ investment required by Infomed). Maybe this is why they gave up 20% of US
  • FDA and Health Canada approval on dialysate bags (1 year?).  Can't use DIMI without that.
  • resolve tubing sourcing and ramp up production capacity for 2025+  (to service US market)
  • await clarity on US insurance coverage for Home Dialysis
  • start 30 person trial in 2023
  • Sometime after or during the above - take on a Distribution partner (partial monetization). 
  • Expand market for SAMI as a portable device that can be used once PMX approved (alongside Baxter's Prism).   Including for Europe (spectral owns that patent)

Little to no Dialco value reflected (yet) in Spectral SP (despite 30% stake in i-Dialco)

If a Spectral/PMX/EAA deal in consumated in 2023, then i-Dialco gets spun out to Spectral shareholders (= monetization).

All JIMHO

MM
<< Previous
Bullboard Posts
Next >>